A new era in therapeutics for diabetic kidney disease
Crossref DOI link: https://doi.org/10.1038/nrneph.2017.182
Published Online: 2018-01-08
Published Print: 2018-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Wanner, Christoph
Text and Data Mining valid from 2018-01-08
Article History
First Online: 8 January 2018
Competing interests
: C.W. has received honoraria for consultancy and speaking from Boehringer-Ingelheim, Sanofi-Genzyme, Astra-Zeneca and Mitsubishi Pharma.